Sex: U
Vaccine: COVID19
Symptoms: Guillain-Barre syndrome
Clinical narrative: Guillain-Barre syndrome; This is a spontaneous report received from a Consumer or other non HCP.  A patient (age and gender not provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 immunization; Bnt162b2 (DOSE 2, SINGLE), for COVID-19 immunization; Bnt162b2 (DOSE 3 (BOOSTER), SINGLE), for COVID-19 immunization. The following information was reported: GUILLAIN-BARRE SYNDROME (life-threatening, hospitalization, disability, medically significant) with onset Aug2023, outcome "not recovered". The patient was hospitalized for guillain-barre syndrome (start date: Aug2023).  Clinical course: Following administration of four Pfizer COVID-19 vaccinations, patient was diagnosed with Guillian-Barre Syndrome in Aug2023, by physicians in the neurological ICU of (Hospital name withheld) in (City name and State name withheld). They also confirmed the probability that the vaccines received were the source of onset. Patient remained at (Hospital name withheld) through September, and subsequently have been transferred to: (Hospital name withheld) in (City name and State name withheld) - Sep2023 - Nov2023), (Hospital name withheld) (City name and State name withheld) - Nov2023 - Dec2023), (Hospital name withheld) ((City name and State name withheld) - Dec2023 - Jun2024), (Hospital name withheld) (City name and State name withheld) - Jun2024 - present) Prior to my diagnosis, Patient was employed by (City name withheld) Transit (a division of the Authority). Patient have had to rely on insurance coverage to cover some of the costs associated with treatment and recovery. But insurance benefits, as you probably know, do not cover all of the costs, nor do they account for the months of strenuous rehabilitation that is necessary to restore independence and return to prior life. Patient was aware of published articles associating (withheld) with the multiple vaccines on the market and know that not the only one who suffered this scary and debilitating disease. Patient also know that recovery of muscular function can be slow and tedious but is quite possible with personal commitment and aggressive physical and occupational therapy. Patient has exhausted insurance benefits, depleted the modest savings accumulated, and have now had to reach into my 401(k) retirement funds to continue recovery. Recently, on the advice of several social. workers, have applied for disability benefits. However, Patient have also been counselled that whatever income receive, will not be sufficient to cover the costs of the type of acute therapy will require to restore ambulation. Nor will it cover the costs of any assistance. will continue to need until I regain full recovery and independence, until this unfortunate occurrence, Patient was a full-time employee, a part-time musician, and a source of assistance to my 83-year-old mother. It is essential that I cease being reliant on a wheelchair, and am Willing and prepared to do whatever it takes to be able to walk again.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 will be requested and submitted if and when received.